Clinical trials in Paderborn

57 clinical trials in Paderborn, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Paderborn at a glance

clinical trials

Not yet recruiting0
Research sites0

Quick filters

57 trials in Paderborn

Open in trial search

Cardiovascular disorder+1

Recruiting

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Zilebesiran
Sponsor:Alnylam Pharmaceuticals Inc.

Contact Research Centre

Cardiovascular disorder+2

Recruiting

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:BI 690517
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Atrial fibrillation

Recruiting

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Investigational

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Investigational

Germany

Participants:65+ years
Substances:Abelacimab
Sponsor:Anthos Therapeutics Inc.

Contact Research Centre

Heart failure with preserved ejection fraction

Recruiting

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:AZD5004
Sponsor:AstraZeneca AB

Contact Research Centre

Hodgkin's disease

Recruiting

A Study of Pembrolizumab and Radiotherapy for Patients with Early-Stage Favorable Classic Hodgkin Lymphoma

Registered drugNo placebo

A Study of Pembrolizumab and Radiotherapy for Patients with Early-Stage Favorable Classic Hodgkin Lymphoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:University Of Cologne

Contact Research Centre

Endometrial cancer metastatic

Recruiting

A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment

Registered drugNo placebo

A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:AZD8205
Sponsor:AstraZeneca AB

Contact Research Centre

Diffuse large B-cell lymphoma+2

Recruiting

Study of loncastuximab tesirine and epcoritamab combination treatment for patients with relapsed or refractory diffuse large B-cell lymphoma

Registered drugNo placebo

Study of loncastuximab tesirine and epcoritamab combination treatment for patients with relapsed or refractory diffuse large B-cell lymphoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:Universitaet Muenster

Contact Research Centre

Triple negative breast cancer

Recruiting

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Breast cancer+1

Recruiting

Study of inavolisib, letrozole and ribociclib in untreated early-stage breast cancer patients with PIK3CA mutation

Registered drugNo placebo

Study of inavolisib, letrozole and ribociclib in untreated early-stage breast cancer patients with PIK3CA mutation

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Inavolisib
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Chronic lymphocytic leukaemia+1

Recruiting

Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo

Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Obinutuzumab
Sponsor:University Of Cologne

Contact Research Centre

Malignant peritoneal neoplasm+2

Recruiting

Comparison of niraparib alone versus niraparib with bevacizumab in patients with newly diagnosed advanced ovarian cancer after chemotherapy with carboplatin and paclitaxel

Registered drugNo placebo

Comparison of niraparib alone versus niraparib with bevacizumab in patients with newly diagnosed advanced ovarian cancer after chemotherapy with carboplatin and paclitaxel

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:AGO Research GmbH

Contact Research Centre

Colon cancer stage III+1

Recruiting

Study on Pre-Operative Chemotherapy with Disodium Folinate, Oxaliplatin, and Fluorouracil for Patients with Advanced Resectable Colon Cancer

Registered drugNo placebo

Study on Pre-Operative Chemotherapy with Disodium Folinate, Oxaliplatin, and Fluorouracil for Patients with Advanced Resectable Colon Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Charite Universitaetsmedizin Berlin KöR

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 513 cities in Germany

Clinical research in Paderborn

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials exploring treatments for various types of breast cancer, including HR-positive, HER2-negative, and triple-negative subtypes. Studies evaluate combination therapies and novel approaches in both early-stage and advanced disease settings.

Endocrine therapy combinations
Immunotherapy approaches
Targeted treatments

Multiple trials focusing on improving survival rates and treatment outcomes for breast cancer patients.

02 Hematologic Malignancies

Comprehensive research into blood cancers, with a focus on chronic lymphocytic leukemia, multiple myeloma, and various lymphomas. Studies examine novel drug combinations and targeted therapies.

Innovative drug combinations
Maintenance therapies
Treatment-naive approaches

Trials aim to improve treatment responses and patient outcomes in various blood cancers.

03 Gastrointestinal Oncology

Studies investigating treatments for colon cancer and other gastrointestinal malignancies. Research focuses on both early-stage and advanced disease, exploring pre-operative and post-operative treatment strategies.

Preoperative chemotherapy
Surgical approaches
Adjuvant therapy optimization

Research aims to improve surgical outcomes and treatment effectiveness in gastrointestinal cancers.

Back to Germany All countries